Novartis Looks to Resurrect Alcon Unit

Novartis is looking to breathe new life into its flagging Alcon business by transferring the unit’s drug products to the pharmaceuticals division.

The move, according to Novartis, will allow Alcon to focus on its core surgical and vision care business.

In addition, Michael Ball has been tapped as the division head and CEO of Alcon, effective Feb. 1. Ball, who was CEO of Hospira until it was bought out by Pfizer, will replace current Alcon head Jeff George.